What's Going On With Pharma Company Indivior's Shares Today?
Portfolio Pulse from Lekha Gupta
Pharmaceutical company Indivior PLC (NASDAQ:INDV) has settled the claims in the In re Suboxone Antitrust Litigation, agreeing to pay $385 million and incurring a charge of $228 million in Q3. This marks the end of the litigation, providing greater certainty for Indivior stakeholders. The company also reported preliminary Q3 results with revenue of $268 million-$273 million and adjusted operating income of $55 million-$65 million. The settlement payment is expected to be made in November 2023.
October 23, 2023 | 3:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Indivior's settlement of the litigation provides certainty for stakeholders and removes a significant legal risk. The cost of the settlement is substantial but manageable given the company's financial results.
The settlement of the litigation removes a significant legal risk for Indivior, which is positive for the company. The cost of the settlement is substantial, but the company's Q3 financial results suggest it is manageable. This could boost investor confidence in the company, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100